Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2025-01-01
|
| Schriftenreihe: | Frontiers in Oncology |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1503262/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|